key: cord-0934708-tniql8ov authors: Dash, Girish C.; Subhadra, Subhra; Turuk, Jyotirmayee; Parai, Debaprasad; Rath, Sonalika; Sabat, Jyotsnamayee; Rout, Usha K.; Kanungo, Srikanta; Choudhary, Hari R.; Nanda, Rashmi R.; Pattnaik, Matrujyoti; Pati, Sanghamitra; Bhattacharya, Debdutta title: Breakthrough SARS‐CoV‐2 infections among BBV‐152 (COVAXIN®) and AZD1222 (COVISHIELD(TM)) recipients: Report from the eastern state of India date: 2021-10-13 journal: J Med Virol DOI: 10.1002/jmv.27382 sha: dd990c2f61c341a83e7c4951ff8773017bf150df doc_id: 934708 cord_uid: tniql8ov In this study, we attempted to record the breakthrough cases reported through passive and voluntary reporting at various healthcare facilities from different districts of Odisha, their clinical presentation, requirement of hospitalization postinfection, and antibody titer against spike antigen. Nasopharyngeal swab and serum samples alongwith demographic, clinical presentation and requirement of hospitalization postinfection were collected from vaccinated individuals through passive and voluntary reporting to various healthcare facilities of Odisha state to detect the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) virus infection and quantitative estimation of antibody titers. A total of 274 samples were found to be positive after 14 days of receiving complete doses of the vaccines. More than 83.2% of the individuals were found to be symptomatic with 9.9% of those required hospitalization. The seropositivity in individuals receiving Covishield (96.7%) was significantly higher than in Covaxin (77.1%). Hospitalized patients were having less median antibody titers than individuals in home isolation. The median age for breakthrough infection among the referred cases was 47.0 years (interquartile range [IQR]: 28.0) with a significantly older age group among Covishield recipients. The median spike receptor binding domain IgG titer values for Covaxin and Covishield recipients were 213.5 AU/ml (IQR: 537.5) and 647.5 AU/ml (IQR: 1645.1), respectively. The results reported here highlight the need for systematic data capture for the breakthrough infections to monitor the emergence of any vaccine escape variants and to plan the next steps in the coronavirus disease‐19 (COVID‐19) vaccine development by understanding the link between clinical protection and measured immunity against SARS‐CoV‐2 infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in December 2019 has caused tremendous panic around the globe for the past one and a half years. During a health crisis wherein the scientific community is trying to contain the effects of the first wave of coronavirus disease-19 (COVID-19), the world was recently struck by a second wave. 1 As of June 20, 2021, more than 178 million individuals were infected with SARS-CoV-2 and 3.86 million SARS-CoV-2-associated deaths were reported. 2 United States, India, and Brazil account for most of the cases worldwide with India recording about 29.88 million cases and 3.86 million deaths. 2, 3 To tackle the ongoing pandemic, the Government of India in- Odisha has vaccinated 9 million citizens with at least a single dose of either BBV-152 or AZD1222 vaccine and among them, 1.9 million people got both the dosages (complete vaccination) as of mid-June. 6 During the early stages of the pandemic, scientists hypothesized that SARS-CoV-2 transmission would be slowed by herd immunity resulting from spontaneous infection, vaccination, or both. 7 Although several studies have demonstrated that SARS-CoV-2 infection in vaccinated individuals presents clinically mild symptoms, it is critical to determine whether severe symptoms can arise in others despite vaccination, as the development of variants is a continuous process. 8 A vaccine breakthrough infection is defined as the detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person ≥14 days after receipt of all recommended doses of an approved COVID-19 vaccine. 9 In the present study, we attempted to record the breakthrough All nasopharyngeal swab samples were tested in an automated machine Cobas 6800 (Roche Molecular Systems), which targets two genes, that is, the ORF1 gene (target 1) and E gene (target 2). Spike receptor binding domain IgG antibodies against SARS-CoV-2 were quantitatively estimated in an automated chemiluminescence electro assay (CLIA)-based platform, ARCHITECT i1000SR (Abbott Diagnostics) using a commercial quantitative kit ARCH SARS-CoV-2 IgG II Quant. The cut-off value for this kit was 50 AU/ml. Statistical Analyses were performed using SPSS version 24 (IBM) and GraphPad Prism 7.00 for Windows (GraphPad Software, La Jolla). Qualitative data were described using frequencies and percentages and analyzed using the χ 2 test. Quantitative data were described using median and interquartile range (IQR) and analyzed using Mann-Whitney U test. A p value of less than 0.05 was considered statistically significant. The study was ethically approved by the institutional human ethical committee of ICMR-Regional Medical Research Centre, Bhubaneswar. A total of 361 samples from vaccinated individuals were referred to our center for confirmation of infection and quantitative antibody estimation. All these 361 individuals were found to be RT-PCR Figure 1 ). There was a marginal increase in the median titer values of symptomatic patients (564.4 AU/ml) than asymptomatic (527.9 AU/ ml) individuals. There was no significant difference between the antibody titers in terms of gender, occupation, hospitalization, and symptom status. The most common symptoms found were fever (88.5%) followed by cough (77.6%) and sore throat (59.6%). Comorbidities, such as diabetes, hypertension, hypothyroidism, and asthma were present in about 64 (23.3%) individuals. The importance of the ongoing battle between immunization and natural selection of potential viral escape mutants is highlighted by our research. SARS-CoV-2 variants will likely be evolved continuously, driven by selection for increased transmissibility and evasion of the host immune response. These results, which are the first of its kind from India, highlight the importance of national surveillance to identify the breakthrough infection and detect the circulating viruses. This will help to monitor the emergence of vaccine escape variants if any. This study urges the need for a larger study, which would help to define correlates of protection to determine whether there is a need to produce modified vaccines or doses and to development of monoclonal antibodies, targeting the conserved spike protein epitopes that are difficult to mutate. The expected second wave of COVID-19 COVID-19) Dashboard Ministry of Health and Family Welfare, Government of India (COVID-19) Dashboard Guidelines of the Indian Society for Sleep Research (ISSR) for practice of sleep medicine during COVID-19 The world's largest COVID-19 vaccination campaign Vaccination Dashboard. MoHFW, Government of India COVID-19 herd immunity: Where are we? COVID-19 Vaccine Breakthrough Infections Reported to CDC-United States COVID-19 Vaccine Effectiveness Research Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine Rates of COVID-19 Among Residents and Staff Members in Nursing Homes-United States Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility Vaccine breakthrough infections with SARS-CoV-2 variants Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans Affairs healthcare system The authors declare that there are no conflict of interests. All data and statistical code to reproduce the tables and figures in the manuscript are available on request to the corresponding author.